HighVista Strategies »

Aeglea Biotherapeutics shares owned by HighVista Strategies

Quarter-by-quarter ownership of Aeglea Biotherapeutics (SYRE) shares owned by HighVista Strategies from 13F filings

Historical chart of HighVista Strategies investment in Aeglea Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aeglea Biotherapeutics held by HighVista Strategies consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aeglea Biotherapeutics by HighVista Strategies

Quarter filed Position value Share count Share price at filing
2024-03-31 $5.9M 154k 37.93

More positions owned by HighVista Strategies

Invesco Db Commdy Indx Trck Unit (DBC)
Apogee Therapeutics (APGE)
Spyre Therapeutics Com New (SYRE)
Merus N V (MRUS)
Microsoft Corporation (MSFT)
Arcellx Common Stock (ACLX)
Xpo Logistics Inc equity (XPO)
Nuvalent Inc-a (NUVL)
Ansys (ANSS)
Hess (HES)
Ideaya Biosciences (IDYA)
Juniper Networks (JNPR)
Sp Plus (SP)
Cerevel Therapeutics Hldng I (CERE)
Albertsons Cos Common Stock (ACI)

View all positions for HighVista Strategies

Top funds holding Aeglea Biotherapeutics

FMR
Perceptive Advisors
Rtw Investments
VR Adviser
Commodore Capital
venBio Select Advisor
Deep Track Capital
Adage Capital Partners GP
Wellington Management Company
Franklin Resources
Citadel Advisors
Driehaus Capital Management
BlackRock
Braidwell
Polar Capital Holdings

View all funds holding Aeglea Biotherapeutics